Evidence map›Paper›PMID 33609066›Full record

Trial reportEuropean journal of heart failure2021

Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.

João Pedro Ferreira, Brian L Claggett, Jiankang Liu, Akshay S Desai, Marc A Pfeffer, Inder S Anand, Dirk J van Veldhuisen, Lars Kober, John G F Cleland, Jean L Rouleau and 9 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in European journal of heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Potassium and Vascular Health: Good Medicine Tastes Bitter.Journal of atherosclerosis and thrombosis · 2022
    Article
  16. Article
  17. Article
  18. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 6 countries.

João Pedro FerreiraNational Institute of Health and Medical Research, Center for Clinical Multidisciplinary Research, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.
Brian L ClaggettCardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Jiankang LiuCardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Akshay S DesaiCardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Marc A PfefferCardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Inder S AnandDepartment of Cardiovascular Medicine, University of Minnesota, Minneapolis, MN, USA.
Dirk J van VeldhuisenDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Lars KoberRigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
John G F ClelandRobertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, Glasgow, UK.
Jean L RouleauMontreal Institute of Cardiology, University of Montreal, Montreal, Canada.
Milton PackerBaylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Michael R ZileMedical University of South Carolina and RHJ Department of Veterans Administration Medical Center, Charleston, SC, USA.
Victor C ShiNovartis, East Hanover, NJ, USA.
Martin P LefkowitzNovartis, East Hanover, NJ, USA.
Sanjiv J ShahDivision of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Orly VardenyMinneapolis VA Center for Care Delivery and Outcomes Research, University of Minnesota, Minneapolis, MN, USA.
Faiez ZannadNational Institute of Health and Medical Research, Center for Clinical Multidisciplinary Research, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
John J V McMurrayBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.ORCID 0000-0002-6317-3975
Brigham and Women's Hospital · USInserm · FRNovartis (United States) · USUniversity of Minnesota · USBaylor University Medical Center · USBritish Heart Foundation · GBCopenhagen University Hospital · DKMedical University of South Carolina · USMontreal Heart Institute · CANorthwestern University · USThe Robertson Trust · GBUniversity Medical Center Groningen · NL

Funding

British Heart Foundation Centre of Research Excellence RE/18/6/34217University of Glasgow
6 · The paper itself

Abstract

aimsThe relationship between serum potassium concentration and outcomes in patients with heart failure and preserved ejection fraction (HFpEF) is not well-established. The aim of this study was to explore the association between serum potassium and clinical outcomes in the PARAGON-HF trial in which 4822 patients with HFpEF were randomised to treatment with sacubitril/valsartan or valsartan. METHODS AND

resultsThe relationship between serum potassium concentrations and the primary study composite outcome of total (first and recurrent) heart failure hospitalisations and cardiovascular death was analysed. Hypo-, normo-, and hyperkalaemia were defined as serum potassium <4 mmol/L, 4-5 mmol/L and >5 mmol/L, respectively. Both screening and time-updated potassium (categorical and continuous spline-transformed) were studied. Patient mean age was 73 years and 52% were women. Patients with higher baseline potassium more often had an ischaemic aetiology and diabetes and mineralocorticoid receptor antagonist treatment. Compared with normokalaemia, both time-updated (but not screening) hypo- and hyperkalaemia were associated with a higher risk of the primary outcome [adjusted hazard ratio (HR) for hypokalaemia 1.55, 95% confidence interval (CI) 1.30-1.85; P < 0.001, and for hyperkalaemia HR 1.21, 95% CI 1.02-1.44; P = 0.025]. Hypokalaemia had a stronger association with a higher risk of all-cause, cardiovascular and non-cardiovascular death than hyperkalaemia. The association of hypokalaemia with increased risk of all-cause and cardiovascular death was most marked in participants with impaired kidney function (interaction P < 0.05). Serum potassium did not significantly differ between sacubitril/valsartan and valsartan throughout the follow-up.

conclusionsBoth hypo- and hyperkalaemia were associated with heart failure hospitalisation but only hypokalaemia was associated with mortality, especially in the context of renal impairment. Hypokalaemia was as strongly associated with death from non-cardiovascular causes as with cardiovascular death. Collectively, these findings suggest that potassium disturbances are a more of a marker of HFpEF severity rather than a direct cause of death.

Indexed as

Heart FailureAgedAminobutyratesAngiotensin Receptor AntagonistsFemaleHumansPotassiumStroke VolumeValsartanAminobutyratesAngiotensin Receptor AntagonistsPotassiumValsartanHeart failure with preserved ejection fractionOutcomesSacubitril/valsartanSerum potassium

Identifiers

PMID33609066
PMCPMC11497244
OpenAlexW3130684163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.